Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus
December 5, 2019 3:52 pmCEO Martin Vidaeus of Redwood Pharma updates industry and shareholders of the status of the RP101 Phase II trial... View Article
CEO Martin Vidaeus of Redwood Pharma updates industry and shareholders of the status of the RP101 Phase II trial... View Article
Redwood Pharma will be arranging RP101 partnering meetings during the upcoming JPMorgan Healthcare Conference between Jan. 13 and Jan. 15,... View Article
REDWOOD PHARMA AB (PUBL) Spotlight Stock Market: REDW redwoodpharma.com Read the quarterly report 1 January – 30 September 2019... View Article
On December 3, CEO Martin Vidaeus from Redwood Pharma will present at BioStock Live (www.biostock.se) in Stockholm. The presentation will... View Article
Redwood Pharma can today report that the last patient received their last dose in the company’s Phase II trial of... View Article
Redwood Pharma will be attending BIO-Europe, Europe’s largest life sciences partnering conference, November 10-12 in Hamburg, Germany, to discuss potential... View Article
On August 27, CEO Martin Vidaeus from Redwood Pharma will present at BioStock Live (www.biostock.se) in Stockholm. The presentation will... View Article
Redwood Pharma AB (publ) today announces that the last patient has now been included in the company’s ongoing Phase II... View Article
Earlier this week, Redwood Pharma published an update on the Phase II clinical trial of RP101 where the company has... View Article
As of today approximately 80 patients have been recruited in Redwood Pharma’s Phase II trial of RP101, the company’s new... View Article